VAUGHAN, Ontario—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company and contact lens maker, announced that it has ended negotiations for a potential sale with a third-party buyer. In December of 2024, as reported in VMAIL, the company said it was exploring a potential sale and other options that would lead to a full separation from parent company Bausch Health Companies Inc. Yesterday, Bausch + Lomb issued the following update on a potential sale, which was disclosed in December following a request from the Canadian Investment Regulatory Organization:

“Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc. After engagement with potential buyers, that process is complete, and will not result in a transaction at this time. Full separation remains the goal. Bausch + Lomb continues to operate as its own entity and execute on its strategies and business plan. The company, which raised 2024 revenue guidance on October 30, will report fourth-quarter and full-year 2024 earnings on February 19, in addition to providing guidance for the 2025 fiscal year.”

When contacted by VMAIL, Bausch + Lomb declined further comment.